INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 168 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,584,264 | -34.7% | 208,231 | +6.4% | 0.01% | -38.5% |
| Q2 2023 | $10,081,142 | +38.9% | 195,728 | +0.5% | 0.01% | +30.0% |
| Q1 2023 | $7,256,879 | +157.2% | 194,711 | +140.8% | 0.01% | +150.0% |
| Q4 2022 | $2,821,624 | -100.0% | 80,872 | -29.3% | 0.00% | -60.0% |
| Q3 2022 | $6,397,963,000 | +148.8% | 114,331 | +130.1% | 0.01% | +150.0% |
| Q2 2022 | $2,571,437,000 | -41.0% | 49,680 | -17.1% | 0.00% | -33.3% |
| Q1 2022 | $4,355,912,000 | -0.3% | 59,941 | +62.2% | 0.01% | 0.0% |
| Q4 2021 | $4,369,914,000 | +136.5% | 36,958 | +168.4% | 0.01% | +100.0% |
| Q3 2021 | $1,847,380,000 | +369.5% | 13,771 | +466.7% | 0.00% | +200.0% |
| Q2 2021 | $393,441,000 | -42.1% | 2,430 | -71.3% | 0.00% | 0.0% |
| Q1 2021 | $679,278,000 | +84.0% | 8,464 | +24.7% | 0.00% | 0.0% |
| Q4 2020 | $369,158,000 | +57.6% | 6,786 | -42.4% | 0.00% | – |
| Q3 2020 | $234,167,000 | +79.3% | 11,779 | +89.6% | 0.00% | – |
| Q2 2020 | $130,597,000 | -48.8% | 6,213 | -70.2% | 0.00% | -100.0% |
| Q1 2020 | $255,313,000 | +225.7% | 20,876 | +290.6% | 0.00% | – |
| Q4 2019 | $78,396,000 | -5.8% | 5,344 | -14.3% | 0.00% | – |
| Q3 2019 | $83,251,000 | +12.8% | 6,236 | +38.3% | 0.00% | – |
| Q2 2019 | $73,829,000 | -43.5% | 4,510 | -41.0% | 0.00% | – |
| Q1 2019 | $130,628,000 | +1203.8% | 7,648 | +942.0% | 0.00% | – |
| Q4 2018 | $10,019,000 | -98.6% | 734 | -84.4% | 0.00% | -100.0% |
| Q3 2018 | $700,990,000 | -7.9% | 4,693 | -41.4% | 0.00% | 0.0% |
| Q2 2018 | $760,882,000 | +983.1% | 8,010 | +140.5% | 0.00% | – |
| Q1 2018 | $70,251,000 | -5.9% | 3,331 | -14.3% | 0.00% | – |
| Q4 2017 | $74,689,000 | +104.2% | 3,886 | +164.0% | 0.00% | – |
| Q3 2017 | $36,579,000 | +52.9% | 1,472 | -1.5% | 0.00% | – |
| Q2 2017 | $23,920,000 | +770.5% | 1,495 | +666.7% | 0.00% | – |
| Q1 2017 | $2,748,000 | -58.7% | 195 | -61.6% | 0.00% | – |
| Q4 2016 | $6,660,000 | -29.9% | 508 | -9.0% | 0.00% | – |
| Q3 2016 | $9,497,000 | +61.2% | 558 | +102.2% | 0.00% | – |
| Q2 2016 | $5,893,000 | – | 276 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |